| 000 | 01558 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515072640.0 | ||
| 264 | 0 | _c20071211 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 024 | 7 |
_a10.1038/sj.leu.2404811 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPlatzbecker, U | |
| 245 | 0 | 0 |
_aLenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. _h[electronic resource] |
| 260 |
_bLeukemia _cNov 2007 |
||
| 300 |
_a2384-5 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCell Proliferation |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 5 |
| 650 | 0 | 4 | _aCytogenetics |
| 650 | 0 | 4 |
_aEarly Growth Response Protein 1 _xgenetics |
| 650 | 0 | 4 | _aGene Deletion |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLenalidomide |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xmethods |
| 650 | 0 | 4 |
_aThalidomide _xanalogs & derivatives |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTransplantation, Homologous _xmethods |
| 700 | 1 | _aMohr, B | |
| 700 | 1 | _avon Bonin, M | |
| 700 | 1 | _aBinder, M | |
| 700 | 1 | _aSchetelig, J | |
| 700 | 1 | _aEhninger, G | |
| 700 | 1 | _aBornhäuser, M | |
| 773 | 0 |
_tLeukemia _gvol. 21 _gno. 11 _gp. 2384-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.leu.2404811 _zAvailable from publisher's website |
| 999 |
_c17119084 _d17119084 |
||